All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome

BACKGROUND: Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing surveillance study was conducted to confirm the real-world safety and efficacy of rituximab in patients of all ages with ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Mana, Kageyama, Yutaro, Ando, Takashi, Sakamoto, Junko, Kimura, Shohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260412/
https://www.ncbi.nlm.nih.gov/pubmed/33796934
http://dx.doi.org/10.1007/s10157-021-02035-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260412/
https://www.ncbi.nlm.nih.gov/pubmed/33796934
http://dx.doi.org/10.1007/s10157-021-02035-6

Ejemplares similares